Glycan Signatures for the Identification of Cisplatin-resistant Testicular Cancer Cell Lines: Specific Glycoprofiling of Human Chorionic Gonadotropin (hCG)

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 Jan 19

PMID 35044085

Authors

Michal Hires

Eduard Jane

Katarina Kalavska

Michal Chovanec

Michal Mego

Peter Kasak

Tomas Bertok

Jan Tkac

Affiliations

Soon will be listed here.

Abstract

Background: Testicular cancer (TC) is the most frequent type of cancer among young men aged between 15 and 34 years. TC is treated using cisplatin, but 3%-5% of TC patients fail to respond to cisplatin, with a very bad to fatal prognosis. Accordingly, it is most important to quickly and readily identify those TC patients who are resistant to cisplatin treatment.

Methods: This study seeks to investigate changes in the glycosylation associated with cisplatin resistance to TC cell lines.

Results: A specific glycoprofiling of human chorionic gonadotropin (hCG) was analysed in three TC cell lines and one cell line of female origin. A typical calibration curve for hCG glycoprofiling showed a dynamic range up to 50 ng/ml, with a limit of detection of 0.3 ng/ml and assay reproducibility represented by relative standard deviation of 3.0%. Changes in the glycan signatures on hCG were analysed in cisplatin-sensitive cell lines and in their cisplatin-resistant sub-lines using an enzyme-linked lectin assay (ELLA) protocol. An immobilised antibody was applied to a selective capture of hCG from a cytoplasmic fraction of cell lysates with final incubation using a lectin from a panel of 17 lectins.

Conclusion: The results suggest that one particular lectin Dolichos biflorus agglutinin (DBA) can selectively discriminate sensitive TC cell lines from resistant TC cell lines. Moreover, there are additional lectins which can provide useful information about the strength of cisplatin resistance.

Citing Articles

N-Acetylated Monosaccharides and Derived Glycan Structures Occurring in N- and O-Glycans During Prostate Cancer Development.

Bertok T, Jane E, Hires M, Tkac J Cancers (Basel). 2024; 16(22).

PMID: 39594740 PMC: 11592093. DOI: 10.3390/cancers16223786.

Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.

Pinkeova A, Kosutova N, Jane E, Lorencova L, Bertokova A, Bertok T Diagnostics (Basel). 2024; 14(7).

PMID: 38611626 PMC: 11011756. DOI: 10.3390/diagnostics14070713.

Glycan signatures for the identification of cisplatin-resistant testicular cancer cell lines: Specific glycoprofiling of human chorionic gonadotropin (hCG).

Hires M, Jane E, Kalavska K, Chovanec M, Mego M, Kasak P Cancer Med. 2022; 11(4):968-982.

PMID: 35044085 PMC: 8855906. DOI: 10.1002/cam4.4515.

References

Bertok T, Jane E, Bertokova A, Lorencova L, Zvara P, Smolkova B . Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. Cancers (Basel). 2020; 12(10). PMC: 7602627. DOI: 10.3390/cancers12102988. View

DallOlio F, Malagolini N, Chiricolo M, Trinchera M, Harduin-Lepers A . The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2. Biochim Biophys Acta. 2013; 1840(1):443-53. DOI: 10.1016/j.bbagen.2013.09.036. View

Shen L, Xia M, Deng X, Ke Q, Zhang C, Peng F . A lectin-based glycomic approach identifies FUT8 as a driver of radioresistance in oesophageal squamous cell carcinoma. Cell Oncol (Dordr). 2020; 43(4):695-707. DOI: 10.1007/s13402-020-00517-5. View

Byrne G, Ahmad-Villiers S, Du Z, McGregor C . B4GALNT2 and xenotransplantation: A newly appreciated xenogeneic antigen. Xenotransplantation. 2018; 25(5):e12394. PMC: 6158069. DOI: 10.1111/xen.12394. View

Pucci M, Gomes Ferreira I, Malagolini N, Ferracin M, DallOlio F . The Sd Synthase B4GALNT2 Reduces Malignancy and Stemness in Colon Cancer Cell Lines Independently of Sialyl Lewis X Inhibition. Int J Mol Sci. 2020; 21(18). PMC: 7555213. DOI: 10.3390/ijms21186558. View

Nakahara S, Miyoshi E, Noda K, Ihara S, Gu J, Honke K . Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line. Mol Cancer Ther. 2003; 2(11):1207-14. View

Engle D, Tiriac H, Rivera K, Pommier A, Whalen S, Oni T . The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019; 364(6446):1156-1162. PMC: 6705393. DOI: 10.1126/science.aaw3145. View

Wu J, Shen L, Qiu L, Duan Q, Luo Z, Dong X . Reversal effect of GnT-V on the radioresistance of human nasopharyngeal carcinoma cells by alteration β1, 6-GlcNAc branched N-glycans. Int J Clin Exp Pathol. 2015; 8(9):9901-11. PMC: 4637784. View

Pan J, Hu Y, Sun S, Chen L, Schnaubelt M, Clark D . Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer. Nat Commun. 2020; 11(1):6139. PMC: 7708455. DOI: 10.1038/s41467-020-19976-3. View

10.

Zhang Z, Zhao Y, Jiang L, Miao X, Zhou H, Jia L . Glycomic alterations are associated with multidrug resistance in human leukemia. Int J Biochem Cell Biol. 2012; 44(8):1244-53. DOI: 10.1016/j.biocel.2012.04.026. View

11.

Dotz V, Wuhrer M . Histo-blood group glycans in the context of personalized medicine. Biochim Biophys Acta. 2016; 1860(8):1596-607. PMC: 7117023. DOI: 10.1016/j.bbagen.2015.12.026. View

12.

Bastian K, Scott E, Elliott D, Munkley J . FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. Int J Mol Sci. 2021; 22(1). PMC: 7795606. DOI: 10.3390/ijms22010455. View

13.

Zhou H, Li Y, Liu B, Shan Y, Li Y, Zhao L . Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene. 2017; 626:106-118. DOI: 10.1016/j.gene.2017.05.030. View

14.

Liu T, Liu R, Zhang S, Guo K, Zhang Q, Li W . Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells. Oncol Lett. 2017; 14(1):517-524. PMC: 5494657. DOI: 10.3892/ol.2017.6177. View

15.

Groux-Degroote S, Wavelet C, Krzewinski-Recchi M, Portier L, Mortuaire M, Mihalache A . B4GALNT2 gene expression controls the biosynthesis of Sda and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract. Int J Biochem Cell Biol. 2014; 53:442-9. DOI: 10.1016/j.biocel.2014.06.009. View

16.

Feng X, Zhao L, Gao S, Song X, Dong W, Zhao Y . Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene. 2015; 578(2):232-41. DOI: 10.1016/j.gene.2015.12.028. View

17.

Narita T, Hatakeyama S, Yoneyama T, Narita S, Yamashita S, Mitsuzuka K . Clinical implications of serum N-glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors. Cancer Med. 2017; 6(4):739-748. PMC: 5387168. DOI: 10.1002/cam4.1035. View

18.

Nakagawa H, Ohira M, Hayashi S, Abe S, Saito S, Nagahori N . Alterations in the glycoform of cisplatin-resistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system. Cancer Lett. 2008; 270(2):295-301. DOI: 10.1016/j.canlet.2008.05.019. View

19.

Lv X, Song J, Xue K, Li Z, Li M, Zahid D . Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. Mol Carcinog. 2019; 58(5):794-807. DOI: 10.1002/mc.22971. View

20.

Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T . Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci. 2020; 21(11). PMC: 7312011. DOI: 10.3390/ijms21114002. View